{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:10:22Z","timestamp":1790244622377,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T00:00:00Z","timestamp":1541462400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4984-3","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T04:39:32Z","timestamp":1541479172000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study"],"prefix":"10.1186","volume":"18","author":[{"given":"Enza","family":"Di Felice","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Roncaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9190-8668","authenticated-orcid":false,"given":"Francesco","family":"Venturelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Mangone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Luminari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Cirilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliano","family":"Carrozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Giorgi Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,6]]},"reference":[{"key":"4984_CR1","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0002-9343(96)00061-7","volume":"100","author":"JE Cortes","year":"1996","unstructured":"Cortes JE, Talpaz M, Kantarjian H. Chronic myelogenous leukemia: a review. Am J Med. 1996;100:555\u201370.","journal-title":"Am J Med"},{"key":"4984_CR2","volume-title":"Anatomia Patologica e correlazioni anatomo-cliniche","author":"GM Mariuzzi","year":"2006","unstructured":"Mariuzzi GM. In: PICCIN, editor. Anatomia Patologica e correlazioni anatomo-cliniche; 2006."},{"key":"4984_CR3","first-page":"1","volume":"40","author":"S Busco","year":"2016","unstructured":"AIRTUM Working Group, Busco S, Buzzoni C, Mallone S, Trama A, Castaing M, et al. Italian cancer figures--report 2015: the burden of rare cancers in Italy. Epidemiol Prev. 2016;40:1\u2013120.","journal-title":"Epidemiol Prev"},{"key":"4984_CR4","unstructured":"Coviello V, Buzzoni C, Fusco M, AIRTUM Working Group. Italian cancer figures - report 2016. Survival of cancer patients in Italy. Epidemiol Prev. 2017;41."},{"key":"4984_CR5","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","volume":"116","author":"M Sant","year":"2010","unstructured":"Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724\u201334.","journal-title":"Blood"},{"key":"4984_CR6","volume-title":"World Heal. Organ","author":"WHO","year":"2018","unstructured":"WHO. The International Classification of Diseases (ICD-11). In: World Heal. Organ; 2018. Available from: \n                    http:\/\/www.who.int\/classifications\/icd\/revision\/en\/\n                    \n                  ."},{"key":"4984_CR7","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/0092-8674(84)90438-0","volume":"37","author":"JB Konopka","year":"1984","unstructured":"Konopka JB, Watanabe SM, Witte ON. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell. 1984;37:1035\u201342.","journal-title":"Cell"},{"key":"4984_CR8","first-page":"100","volume":"56","author":"E Buchdunger","year":"1996","unstructured":"Buchdunger E, Zimmermann J, Mett H, Meyer T, M\u00fcller M, Druker BJ, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56:100\u20134.","journal-title":"Cancer Res"},{"key":"4984_CR9","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose Cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994\u20131004.","journal-title":"N Engl J Med"},{"key":"4984_CR10","unstructured":"EMA. European Medicines Agency - Imatinib. 2001 [cited 2017 Jun 26]. Available from: \n                    http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000406\/human_med_000808.jsp&mid=WC0b01ac058001d124"},{"key":"4984_CR11","doi-asserted-by":"publisher","first-page":"i52","DOI":"10.1093\/annonc\/mdi807","volume":"16","author":"B Simonsson","year":"2005","unstructured":"Simonsson B, Kloke O, Stahel RA. ESMO minimum clinical recommendations for the diagnosis, treatment and follow-up of chronic myelogenous leukemia (CML). Ann Oncol. 2005;16:i52\u20133.","journal-title":"Ann Oncol"},{"issue":"5","key":"4984_CR12","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3324\/haematol.2015.139337","volume":"101","author":"T. I. Mughal","year":"2016","unstructured":"Mughal TI, Radich JP, Deininger MW, Apperley JF, Hughes TP, Harrison CJ, et al. Chronic myeloid leukemia: reminiscences and dreams. Haematologica. 2016:541\u201358.","journal-title":"Haematologica"},{"key":"4984_CR13","doi-asserted-by":"publisher","first-page":"e0168947","DOI":"10.1371\/journal.pone.0168947","volume":"12","author":"H Banjar","year":"2017","unstructured":"Banjar H, Ranasinghe D, Brown F, Adelson D, Kroger T, Leclercq T, et al. Modelling predictors of molecular response to frontline Imatinib for patients with chronic myeloid Leukaemia. PLoS One. 2017;12:e0168947.","journal-title":"PLoS One"},{"issue":"7","key":"4984_CR14","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","volume":"110","author":"T. O'Hare","year":"2007","unstructured":"O\u2019Hare T, Eide CA, Deininger MWN. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007:2242\u20139.","journal-title":"Blood"},{"key":"4984_CR15","doi-asserted-by":"publisher","first-page":"v165","DOI":"10.1093\/annonc\/mdq201","volume":"21","author":"M Baccarani","year":"2010","unstructured":"Baccarani M, Dreyling M. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:v165\u20137.","journal-title":"Ann Oncol"},{"key":"4984_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179700","volume":"12","author":"C Woywod","year":"2017","unstructured":"Woywod C, Gruber FX, Engh RA, Fl\u00e5 T. Dynamical models of mutated chronic myelogenous leukemia cells for a postimatinib treatment scenario: response to dasatinib or nilotinib therapy. PLoS One. 2017;12:e0179700.","journal-title":"PLoS One"},{"key":"4984_CR17","unstructured":"EMA. European Medicines Agency - Dasatinib. 2006 [cited 2017 Jun 26]. Available from: \n                    http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000709\/human_med_001062.jsp&mid=WC0b01ac058001d124"},{"key":"4984_CR18","unstructured":"EMA. European Medicines Agency - Nilotinib. 2007 [cited 2017 Jun 26]. Available from: \n                    http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000798\/human_med_001079.jsp&mid=WC0b01ac058001d124"},{"key":"4984_CR19","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Giles F, Wunderle L, Bhalla K, O\u2019Brien S, Wassmann B, et al. Nilotinib in Imatinib-resistant CML and Philadelphia chromosome\u2013positive ALL. N Engl J Med. 2006;354:2542\u201351.","journal-title":"N Engl J Med"},{"key":"4984_CR20","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260\u201370.","journal-title":"N Engl J Med"},{"key":"4984_CR21","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim D-W, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251\u20139.","journal-title":"N Engl J Med"},{"key":"4984_CR22","doi-asserted-by":"publisher","first-page":"vii72","DOI":"10.1093\/annonc\/mds228","volume":"23","author":"M Baccarani","year":"2012","unstructured":"Baccarani M, Pileri S, Steegmann J-L, Muller M, Soverini S, Dreyling M, et al. Chronic myeloid leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23:vii72\u20137.","journal-title":"Ann Oncol"},{"key":"4984_CR23","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving Imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408\u201317.","journal-title":"N Engl J Med"},{"key":"4984_CR24","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1634\/theoncologist.2010-0393","volume":"16","author":"D Pulte","year":"2011","unstructured":"Pulte D, Gondos A, Redaniel MT, Brenner H. Survival of patients with chronic myelocytic leukemia: comparisons of estimates from clinical trial settings and population-based cancer registries. Oncologist. 2011;16:663\u201371.","journal-title":"Oncologist"},{"key":"4984_CR25","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","volume":"29","author":"M Bj\u00f6rkholm","year":"2011","unstructured":"Bj\u00f6rkholm M, Ohm L, Eloranta S, Derolf \u00c5, Hultcrantz M, Sj\u00f6berg J, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol. 2011;29:2514\u201320.","journal-title":"J Clin Oncol"},{"key":"4984_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004266","volume":"4","author":"AG Smith","year":"2014","unstructured":"Smith AG, Painter D, Howell DA, Evans P, Smith G, Patmore R, et al. Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort. BMJ Open. 2014;4:e004266.","journal-title":"BMJ Open"},{"key":"4984_CR27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1756-8722-6-70","volume":"6","author":"D Pulte","year":"2013","unstructured":"Pulte D, Barnes B, Jansen L, Eisemann N, Emrich K, Gondos A, et al. Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century. J Hematol Oncol. 2013;6:70.","journal-title":"J Hematol Oncol"},{"key":"4984_CR28","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1002\/cncr.28106","volume":"119","author":"AM Brunner","year":"2013","unstructured":"Brunner AM, Campigotto F, Sadrzadeh H, Drapkin BJ, Chen Y-B, Neuberg DS, et al. Trends in all-cause mortality among patients with chronic myeloid leukemia. Cancer. 2013;119:2620\u20139.","journal-title":"Cancer"},{"key":"4984_CR29","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.3109\/10428194.2012.745525","volume":"54","author":"Y Chen","year":"2013","unstructured":"Chen Y, Wang H, Kantarjian H, Cortes J. Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. Leuk Lymphoma. 2013;54:1411\u20137.","journal-title":"Leuk Lymphoma"},{"key":"4984_CR30","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(14)70282-7","volume":"15","author":"M Sant","year":"2014","unstructured":"Sant M, Minicozzi P, Mounier M, Anderson LA, Brenner H, Holleczek B, et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol. 2014;15:931\u201342.","journal-title":"Lancet Oncol"},{"key":"4984_CR31","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12885-016-2238-9","volume":"16","author":"T Beinortas","year":"2016","unstructured":"Beinortas T, Tavorien\u0117 I, \u017dvirblis T, Gerbutavi\u010dius R, Jurgutis M, Gri\u0161kevi\u010dius L. Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological disease registry 2000\u20132013. BMC Cancer. 2016;16:198.","journal-title":"BMC Cancer"},{"issue":"3","key":"4984_CR32","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3324\/haematol.2012.082511","volume":"99","author":"L. Noens","year":"2014","unstructured":"Noens L, Hensen M, Kucmin-Bemelmans I, Lofgren C, Gilloteau I, Vrijens B. Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges. Haematologica. 2014:437\u201347.","journal-title":"Haematologica"},{"key":"4984_CR33","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/bjh.13843","volume":"172","author":"A Kurtovic-Kozaric","year":"2016","unstructured":"Kurtovic-Kozaric A, Hasic A, Radich JP, Bijedic V, Nefic H, Eminovic I, et al. The reality of cancer treatment in a developing country: the effects of delayed TKI treatment on survival, cytogenetic and molecular responses in chronic myeloid leukaemia patients. Br J Haematol. 2016;172:420\u20137.","journal-title":"Br J Haematol"},{"issue":"1","key":"4984_CR34","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/j.1365-2141.2011.08653.x","volume":"155","author":"Paolo Gallipoli","year":"2011","unstructured":"Gallipoli P, Shepherd P, Irvine D, Drummond M, Holyoake T. Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a west of Scotland and Lothian population study. Br J Haematol. 2011:128\u201330.","journal-title":"British Journal of Haematology"},{"key":"4984_CR35","first-page":"i","volume":"96","author":"HAEMACARE Working Group","year":"2010","unstructured":"HAEMACARE Working Group. Manual for coding and reporting haematological malignancies. Tumori. 2010;96:i\u2013A32.","journal-title":"Tumori"},{"key":"4984_CR36","unstructured":"EMA Committee for Orphan Medicinal Products. EMA\/COMP\/10370\/2003 Rev.5 2015 [cited 2017 Jun 26]. p. 4. Available from: \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Orphan_designation\/2009\/10\/WC500006437.pdf"},{"key":"4984_CR37","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1182\/blood-2013-04-495598","volume":"122","author":"M H\u00f6glund","year":"2013","unstructured":"H\u00f6glund M, Sandin F, Hellstr\u00f6m K, Bj\u00f6reman M, Bj\u00f6rkholm M, Brune M, et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood. 2013;122:1284\u201392.","journal-title":"Blood"},{"key":"4984_CR38","unstructured":"National Cancer Institute. Joinpoint regression program - surveillance. Res Prog. 2015. Available from:\u00a0\n                    https:\/\/surveillance.cancer.gov\/joinpoint\/\n                    \n                  ."},{"key":"4984_CR39","first-page":"348","volume":"46","author":"JL Bernal","year":"2017","unstructured":"Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol. 2017;46:348\u201355.","journal-title":"Int J Epidemiol"},{"key":"4984_CR40","volume-title":"Stat. Softw. Components. Boston College Department of Economics","author":"A Linden","year":"2015","unstructured":"Linden A. ITSA: Stata module to perform interrupted time series analysis for single and multiple groups. In: Stat. Softw. Components. Boston College Department of Economics; 2015."},{"key":"4984_CR41","unstructured":"EMA Committee for Orphan Medicinal Products. EMA\/COMP\/10367\/2003 Rev.4. 2015 [cited 2017 Jun 26]. p. 4. Available from: \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Orphan_designation\/2009\/10\/WC500006425.pdf"},{"key":"4984_CR42","unstructured":"EMA Committee for Orphan Medicinal Products. EMA\/COMP\/244136\/2005 Rev.4. 2015 [cited 2017 Jun 26]. p. 4. Available from: \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Orphan_designation\/2009\/10\/WC500006421.pdf"},{"key":"4984_CR43","unstructured":"EMA Committee for Orphan Medicinal Products. EMA\/COMP\/275619\/2005 Rev.4. 2015 [cited 2017 Jun 26]. p. 5. Available from: \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Orphan_designation\/2009\/10\/WC500006417.pdf"},{"key":"4984_CR44","unstructured":"EMA Committee for Orphan Medicinal Products. EMA\/COMP\/244140\/2005 Rev.4. 2015 [cited 2017 Jun 26]. p. 4. Available from: \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Orphan_designation\/2009\/10\/WC500006408.pdf"},{"key":"4984_CR45","unstructured":"EMA Committee for Orphan Medicinal Products. EMA\/COMP\/386759\/2005 Rev.4. 2015 [cited 2017 Jun 26]. p. 4. Available from: \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Orphan_designation\/2009\/10\/WC500006448.pdf"},{"key":"4984_CR46","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/ajh.24591","volume":"92","author":"F Castagnetti","year":"2017","unstructured":"Castagnetti F, Di Raimondo F, De Vivo A, Spitaleri A, Gugliotta G, Fabbiano F, et al. A population-based study of chronic myeloid leukemia patients treated with imatinib in first line. Am J Hematol. 2017;92:82\u20137.","journal-title":"Am J Hematol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4984-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4984-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4984-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T19:15:29Z","timestamp":1572981329000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4984-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,6]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4984"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4984-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,6]]},"assertion":[{"value":"4 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Data were treated according to the Italian Data Protection legislation (D.Lgs.n.196\/2003). The Reggio Emilia cancer registry received approval from the Provincial Ethical Committee on July 23, 2014 (Comitato Etico Provinciale of Reggio Emilia, now Comitato Etico AVEN, after being merged with the other Ethics Committees of the Modena, Piacenza and Parma provinces ). The study was sponsored and conducted by the Cancer Registry Directorate (LM and PGR) and the aims of this research are among those envisaged by the ethical committee.This is a retrospective observational study based on cancer registry data. In accordance with the Italian privacy law, no patient or parental consent is required for large retrospective population-based studies approved by the competent Ethics Committee if data are published only in aggregated form.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"1069"}}